Clinical Commander

Back to dossier
uro.nocturia-eval.v1PRODUCTION
uro.nocturia-eval.v1

Nocturia — chronic outpatient evaluation (nocturnal polyuria / reduced bladder capacity / 24-h polyuria / sleep / med / BPH / CHF / CKD / pregnancy / aging)

urologychronicadultgeriatric
Hard-required inputs
0 / 18
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Adult / geriatric outpatient with chronic nocturia ≥2 voids/night with bother; identify dominant phenotype (nocturnal polyuria / reduced bladder capacity / 24-h polyuria / sleep / med / comorbid CHF / DM / DI / hypercalcemia / OSA / BPH / CKD / pregnancy / aging) (AUA OAB 2019)

Inputs
2
Actions
0
Advance rule
Set
Advance when

engine scope confirmed

Patient inputs (23)

Excessive evening fluid / caffeine / alcohol drives nocturnal polyuria — behavioral modification primary intervention

Loop diuretic evening dose drives nocturia — shift to morning; SSRI / TCA / CCB / lithium / bisphosphonate timing adjustment (Beers / STOPP)

CHF nighttime supine-diuresis pattern — evening fluid restriction + morning diuretic + leg elevation late afternoon (cardio.acute-hf.core.v1)

DM / DI / hypercalcemia / SIADH cause 24-h global polyuria pattern; gates endo / neph workup (endo.dm2.core.v1; neph.ckd.core.v1)

OSA causes nocturia via ANP release (negative intrathoracic pressure); PSG indicated; CPAP improves nocturia

BPH causes nocturia via reduced functional capacity + obstruction; α-blocker bridge; route uro.bph.v1

Pregnancy physiologic nocturia from uterine pressure on bladder + increased GFR — reassurance + minor lifestyle measures

ICS definition ≥1 voiding (any waking void counts); bother typically at ≥2; serial diary tracking (AUA OAB 2019)

Aging is a major contributor; >65 yo trigger for desmopressin hyponatremia caution (AUA OAB 2019; FDA desmopressin warning)

Male: BPH overlay; female: OAB / mixed UI overlay; pregnancy phenotype

3-day FVC is THE diagnostic artifact — quantifies 24-h output, nocturnal output, nocturnal polyuria index (NPi = nocturnal output / 24-h output) (AUA OAB 2019)

PVR — high (>250 mL) gates BPH overlay + antimuscarinic caution (AUA BPH 2021)

Rule UTI + hematuria + glucosuria + casts; transient cause screen (AUA OAB 2019)

Rule DM polyuria — glucose / HbA1c (endo.dm2.core.v1)

Baseline for desmopressin safety + screen SIADH / hypernatremia (FDA desmopressin warning)

Baseline renal function — CKD concentrating defect (neph.ckd.core.v1)

Desmopressin requires baseline sodium + recheck at 1 wk; older / loop-diuretic / SSRI heighten risk (FDA warning)

Baseline BP for diuretic / α-blocker / β3 agonist initiation; orthostasis screening (AUA OAB 2019)

CKD impairs urinary concentration → fixed isosthenuria → nocturia from nocturnal polyuria; route neph.ckd.core.v1

Depression / anxiety can affect sleep architecture and bladder perception; SSRI may be implicated (Beers)

Rule hypercalcemia (polyuria from nephrogenic DI pattern) (workup.hypercalcemia)

BNP for CHF screening if nighttime supine-diuresis pattern (cardio.acute-hf.core.v1)

Fever + nocturia → UTI workup (transient cause); rule out before chronic phenotyping (AUA OAB 2019)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (11)

11 need judgement
  • informationalmoderatenocturnal_polyuria_dominant
    Nocturnal polyuria dominant (NPi >33% of 24-h output overnight; >20% in young patient on FVC); desmopressin first-line if ≤65 yo with normal baseline Na (AUA OAB 2019; FDA Noctiva)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatereduced_bladder_capacity
    Reduced bladder capacity — small voided volumes on FVC with normal 24-h output; OAB workup → antimuscarinic / β3 / botox (AUA OAB 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderate24h_polyuria_global
    24-h global polyuria (>40 mL/kg or >3 L/day) — DM / DI / hypercalcemia / SIADH / medication workup; treat underlying cause (AUA OAB 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatesleep_disorder_dominant_OSA
    OSA-dominant nocturia — PSG indicated; CPAP improves nocturia via reducing ANP release from negative intrathoracic pressure (AASM)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateBPH_associated
    BPH-associated nocturia — α-blocker bridge + route to uro.bph.v1 for full BPH ladder (α-blocker + 5-ARI + PDE5i + surgery) (AUA BPH 2021)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateCHF_associated_nighttime_supine_diuresis
    CHF-associated nocturia — nighttime supine diuresis from dependent edema redistribution; evening fluid restriction + diuretic timing + afternoon leg elevation + GDMT; route cardio.acute-hf.core.v1 (AHA/ACC HF 2022)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateCKD_related_nocturia
    CKD-related nocturia — impaired urinary concentration → fixed isosthenuria → nocturnal polyuria pattern; route to neph.ckd.core.v1 for primary CKD management (KDIGO 2026)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildmedication_induced
    Medication-induced nocturia — loop diuretic evening dose / CCB lower-extremity edema / SSRI / TCA / lithium / bisphosphonate; timing adjustment + deprescribing (Beers / STOPP)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildpregnancy_nocturia_physiologic
    Pregnancy physiologic nocturia — uterine pressure on bladder + increased GFR; reassurance + minor lifestyle measures (ACOG)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildaging_normal
    Aging-related nocturia — normal physiologic change with age; falls-risk dominant concern; bedside commode + lighting + PT + deprescribing review (AGS / AUA OAB 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildbehavioral_excessive_evening_fluid
    Behavioral excessive evening fluid / caffeine / alcohol intake — primary lifestyle modification; common reversible cause (AUA OAB 2019)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

Nocturia phenotype-specific ladder: behavioral first / med-timing adjustment / desmopressin (nocturnal polyuria ≤65) / antimuscarinic-β3 (reduced bladder capacity) / α-blocker (BPH) / CPAP (OSA) / CHF evening restriction + diuretic timing / route comorbid engines
axis: nocturia_phenotype_ladderstep 1 - STEP 1 — Behavioral + lifestyle (all phenotypes)
Selected step "STEP 1 — Behavioral + lifestyle (all phenotypes)" — All phenotypes; first-line for all
  • Limit evening fluid / caffeine / alcohol after 6 PM; afternoon leg elevation if dependent edema; compression stockings; appropriate sleep hygiene
    first line
    lifestyle
    triggers: all_phenotypes
    AUA OAB 2019 — behavioral first-line for nocturia (PMID 31039103;)
  • Pre-bed bladder emptying + voiding-schedule diary
    first line
    lifestyle
    triggers: all_phenotypes
    AUA OAB 2019

outpatient playbook — drug actions (5)

  1. 1. desmopressin (nocturnal polyuria ≤65)
    Female 0.83 mcg nasal / 27.7 mcg PO sublingual; male 1.66 mcg nasal / 55.3 mcg PO sublingual; check Na at 1 wk • nasal / PO sublingual • once nightly
    trigger: Nocturnal polyuria dominant phenotype, ≤65 yo, baseline Na ≥135, no loop diuretic / SSRI concurrent (AUA OAB 2019; FDA)
    AUA OAB 2019 — sex-specific dosing
  2. 2. mirabegron / vibegron (reduced bladder capacity)
    Mirabegron 25 mg PO daily titrate to 50 mg; vibegron 75 mg daily • PO • once daily
    trigger: Reduced bladder capacity / OAB overlay; elderly / cognitive concern (AUA OAB 2019)
    β3 preferred elderly
  3. 3. trospium (reduced bladder capacity elderly)
    20 mg PO BID OR 60 mg ER daily • PO • BID or daily ER
    trigger: Reduced bladder capacity, elderly, antimuscarinic preferred
    AUA OAB 2019 — preferred elderly
  4. 4. tamsulosin (BPH-associated nocturia)
    0.4 mg PO daily • PO • once daily
    trigger: BPH overlay with voiding LUTS + nocturia (AUA BPH 2021)
    AUA BPH 2021 — uroselective α-blocker
  5. 5. onabotulinumtoxinA (refractory OAB component)
    100 U intradetrusor q6mo PRN • intradetrusor • q6mo PRN
    trigger: Refractory OAB with nocturia component
    AUA OAB 2019

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Patient reports ≥2 voids per night that wake them; ICS definition of nocturia (AUA OAB 2019); Nocturia causing sleep disruption / daytime fatigue / falls in elderly — symptom-driven evaluation; Established BPH with nocturia component — α-blocker bridge + FVC for nocturnal polyuria overlap (uro.bph.v1).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Nocturia — chronic outpatient evaluation (nocturnal polyuria / reduced bladder capacity / 24-h polyuria / sleep / med / BPH / CHF / CKD / pregnancy / aging)** (uro.nocturia-eval.v1).
Phenotype framing: Nocturnal polyuria dominant (NPi >33% / >20% young), reduced bladder capacity, 24-h global polyuria (DM / DI / hypercalcemia / SIADH workup), OSA-dominant, medication-induced, BPH-associated, CHF-associated, pregnancy, aging-normal, behavioral evening fluid, CKD concentrating defect (AUA OAB 2019)
Scope: Adult / geriatric outpatient with chronic nocturia ≥2 voids/night with bother; identify dominant phenotype (nocturnal polyuria / reduced bladder capacity / 24-h polyuria / sleep / med / comorbid CHF / DM / DI / hypercalcemia / OSA / BPH / CKD / pregnancy / aging) (AUA OAB 2019)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Nocturia phenotype-specific ladder: behavioral first / med-timing adjustment / desmopressin (nocturnal polyuria ≤65) / antimuscarinic-β3 (reduced bladder capacity) / α-blocker (BPH) / CPAP (OSA) / CHF evening restriction + diuretic timing / route comorbid engines** — step "STEP 1 — Behavioral + lifestyle (all phenotypes)".
1. Limit evening fluid / caffeine / alcohol after 6 PM; afternoon leg elevation if dependent edema; compression stockings; appropriate sleep hygiene (lifestyle, first line) — AUA OAB 2019 — behavioral first-line for nocturia (PMID 31039103;)
2. Pre-bed bladder emptying + voiding-schedule diary (lifestyle, first line) — AUA OAB 2019

Setting playbook (outpatient) — Comprehensive eval at index visit (FVC + UA + Na + creatinine + PVR); phenotype assignment at visit 2; ladder step at visit 3; 4-wk re-check on each step (AUA OAB 2019)
3. desmopressin (nocturnal polyuria ≤65) Female 0.83 mcg nasal / 27.7 mcg PO sublingual; male 1.66 mcg nasal / 55.3 mcg PO sublingual; check Na at 1 wk nasal / PO sublingual once nightly — Nocturnal polyuria dominant phenotype, ≤65 yo, baseline Na ≥135, no loop diuretic / SSRI concurrent (AUA OAB 2019; FDA) (AUA OAB 2019 — sex-specific dosing)
4. mirabegron / vibegron (reduced bladder capacity) Mirabegron 25 mg PO daily titrate to 50 mg; vibegron 75 mg daily PO once daily — Reduced bladder capacity / OAB overlay; elderly / cognitive concern (AUA OAB 2019) (β3 preferred elderly)
5. trospium (reduced bladder capacity elderly) 20 mg PO BID OR 60 mg ER daily PO BID or daily ER — Reduced bladder capacity, elderly, antimuscarinic preferred (AUA OAB 2019 — preferred elderly)
6. tamsulosin (BPH-associated nocturia) 0.4 mg PO daily PO once daily — BPH overlay with voiding LUTS + nocturia (AUA BPH 2021) (AUA BPH 2021 — uroselective α-blocker)
7. onabotulinumtoxinA (refractory OAB component) 100 U intradetrusor q6mo PRN intradetrusor q6mo PRN — Refractory OAB with nocturia component (AUA OAB 2019)

Non-pharmacologic actions:
- Evening fluid / caffeine / alcohol limit after 6 PM (AUA OAB 2019)
- Afternoon leg elevation + compression stockings if dependent edema (CHF) (AUA OAB 2019)
- Sleep hygiene counseling (AASM)
- Pre-bed bladder emptying + voiding schedule
- Medication timing shift — diuretic to morning (AUA OAB 2019)
- Fall prevention — bedside commode, lighting, PT (AGS)
- Comorbid routing — CHF → cardio.acute-hf.core.v1; DM → endo.dm2.core.v1; CKD → neph.ckd.core.v1; BPH → uro.bph.v1; reduced capacity → uro.urinary-incontinence-eval.v1
- PSG referral if OSA suspected (AASM)
- Pregnancy reassurance + minor lifestyle
- Caregiver education + return precautions

AVOID / contraindication checks:
- Desmopressin_AVOID_over_65_hyponatremia_risk (FDA / AUA OAB 2019)
- Desmopressin_baseline_and_serial_sodium_required_at_1wk_1mo_3mo_and_when_ill (FDA)
- Desmopressin_AVOID_with_concurrent_loop_diuretic_or_SSRI_hyponatremia (FDA)
- Desmopressin_AVOID_in_SIADH_or_heart_failure_volume_overload (FDA)
- Antimuscarinic_AVOID_PVR_gt_250mL (AUA OAB 2019)
- Antimuscarinic_anticholinergic_burden_dementia_risk_elderly (AGS Beers)
- Beta3_BP_monitoring (AUA OAB 2019)
- CPAP_adherence_required_for_OSA_benefit (AASM)
- Rule_out_UTI_DM_DI_hypercalcemia_before_chronic_phenotyping (AUA OAB 2019)
- Falls_risk_assessment_in_elderly_with_nocturia (AGS / AUA OAB 2019)

Monitoring

Regimen monitoring:
- FVC at 4wk phenotype response (AUA OAB 2019)
- serum sodium at 1wk 1mo 3mo on desmopressin and when ill (FDA)
- BP HR q3mo on beta3 or alpha blocker (AUA OAB 2019; AUA BPH 2021)
- PVR at 12wk on antimuscarinic (AUA OAB 2019)
- cognition MMSE q6mo on antimuscarinic elderly (AGS Beers)
- CPAP adherence AHI at 3mo (AASM)
- nocturia episodes per night diary at each visit (AUA OAB 2019)
- falls screen annual in elderly (AGS)

Setting (outpatient) monitoring:
- 4 wk re-eval on each ladder step (AUA OAB 2019)
- FVC at each visit
- Sodium at 1 wk + 1 mo + 3 mo + when ill on desmopressin (FDA)
- BP on diuretic / α-blocker / β3 (AUA OAB 2019)
- PVR on antimuscarinic (AUA OAB 2019)
- Cognition q6mo on antimuscarinic elderly (AGS Beers)
- CPAP adherence at 3 mo (AASM)
- Falls screen annual (AGS)

Follow-up plan: Annual re-eval; deprescribing review on diuretic / desmopressin / antimuscarinic in elderly; reassess phenotype if symptoms change (AUA OAB 2019; Beers)
- Close-out criterion: follow-up scheduled

Monitoring phase: FVC at 4 wk; episodes per night + bother; sodium at 1 wk + 1 mo + 3 mo on desmopressin; BP on diuretic / α-blocker / β3 (AUA OAB 2019; FDA)

Disposition

Current setting: outpatient — Comprehensive eval at index visit (FVC + UA + Na + creatinine + PVR); phenotype assignment at visit 2; ladder step at visit 3; 4-wk re-check on each step (AUA OAB 2019)

Disposition criteria:
- Stable on ladder step → annual re-eval (AUA OAB 2019)
- Refractory → uro / urogyn / sleep / specialty referral
- Comorbid dominance → route to comorbid engine for primary management

Escalation triggers (move to higher acuity):
- Hyponatremia on desmopressin → STOP + workup + reassess (FDA)
- New AUR / hematuria → urology (AUA microhematuria 2020)
- Worsening CHF → ED / cardiology (cardio.acute-hf.core.v1)
- Falls → STAT geriatric assessment (AGS)
- Refractory to ≥3 ladder steps → uro / urogyn referral

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [MODERATE] Nocturnal polyuria dominant (NPi >33% of 24-h output overnight; >20% in young patient on FVC); desmopressin first-line if ≤65 yo with normal baseline Na (AUA OAB 2019; FDA Noctiva)
- [MODERATE] Reduced bladder capacity — small voided volumes on FVC with normal 24-h output; OAB workup → antimuscarinic / β3 / botox (AUA OAB 2019)
- [MODERATE] 24-h global polyuria (>40 mL/kg or >3 L/day) — DM / DI / hypercalcemia / SIADH / medication workup; treat underlying cause (AUA OAB 2019)

Citations

- AUA OAB 2019 + amendments + NICE UI 2019 + FDA Noctiva (desmopressin) + AASM OSA + ICS / EAU nocturia + AGS Beers (deprescribing) + AHA/ACC HF 2022 (CHF nocturia) [PMID:31039103](https://pubmed.ncbi.nlm.nih.gov/31039103/)

Last reconciled with current guidelines: 2026-05-22.
References
  • AUA OAB 2019 + amendments + NICE UI 2019 + FDA Noctiva (desmopressin) + AASM OSA + ICS / EAU nocturia + AGS Beers (deprescribing) + AHA/ACC HF 2022 (CHF nocturia) — PMID:31039103